Giuseppe Battaglia | Group Leader / ICREA Research Professor
Azzurra Apriceno | Postdoctoral Researcher
José Rui Pereira | Postdoctoral Researcher
Lara Aiassa | PhD Student
Claudia Di Guglielmo | Laboratory Technician
About
We are chemists, physicists, mathematicians, engineers, biologists who work alongside to design bionic units that mimic specific biological functions and/or introduce operations that do not exist in Nature. We apply a constructionist approach where we mimic biological complexity in the form of design principles to produce functional units from simple building blocks and their interactions. We called such an approach: Molecular Bionics.
We are engaged in several activities involving the synthesis and characterisation of novel hierarchal materials whose properties are the result of the holistic combination of its components:
Molecular engineering
We combine synthetic and supramolecular chemistry to tune inter/intramolecular interactions and self-assembly processes to form dynamic soft materials whose molecular, supramolecular and mesoscale structures are tuned and fit for the final application (pictured right: molecular engineering of nanoscopic structures starting from molecule passing to polymers and finally to supra molecular structures).
Physical biology

Figure 1 Giant polymersomes formed by 2D printing (Howse et al Nature Materials 2009)
Our materials are designed to interact with living systems and thus its biological activity is studied in high detail. We have developed and established new methodologies to study living systems and how synthetic materials interact with them combining holistically physical and life sciences (Physical Biology).
Synthetic biology

Figure 2; The brain vasculature (red) of a mouse surronded by astrocytes (cyan) and neurons (white) (Matias-Lorenço et al in preparation )
Both know-hows are applied to study biological organisation and complexity creating synthetic surrogates that act as models, as well as to engineer novel sophisticated ways to interact with living organisms.
Somanautics
In analogy to medical bionics, where engineering and physical science converge to the design of replacement and/or enhancement of malfunctioning body parts, we take inspiration from viruses, trafficking vesicles and exosomes to apply molecular engineering to create nanoscopic carriers that can navigate the human body (Somanautics) with the final aim to improve drug delivery or create new diagnostic tools.
Visit our external website to find out more.
Projects
Publications
Donnelly, Joanna L., Offenbartl-Stiegert, Daniel, Marín-Beloqui, José M., Rizzello, Loris, Battaglia, Guiseppe, Clarke, Tracey M., Howorka, Stefan, Wilden, Jonathan D., (2020). Exploring the relationship between BODIPY structure and spectroscopic properties to design fluorophores for bioimaging Chemistry - A European Journal 26, (4), 863-872
Tian, Xiaohe, Angioletti-Uberti, Stefano, Battaglia, Giuseppe, (2020). On the design of precision nanomedicines Science Advances 6, (4), eaat0919
Tian, Xiaohe, Leite, Diana M., Scarpa, Edoardo, Nyberg, Sophie, Fullstone, Gavin, Forth, Joe, Matias, Diana, Apriceno, Azzurra, Poma, Alessandro, Duro-Castano, Aroa, Vuyyuru, Manish, Harker-Kirschneck, Lena, Šarić, Zhang, Zhongping, Xiang, Pan, Fang, Bin, Tian, Yupeng, Luo, Lei, Rizzello, Loris, Battaglia, Giuseppe, (2020). On the shuttling across the blood-brain barrier via tubule formation: Mechanism and cargo avidity bias Science Advances 6, (48), eabc4397
Gouveia, Virgínia M., Rizzello, Loris, Nunes, Claudia, Poma, Alessandro, Ruiz-Perez, Lorena, Oliveira, António, Reis, Salette, Battaglia, Giuseppe, (2019). Macrophage targeting pH responsive polymersomes for glucocorticoid therapy Pharmaceutics 11, (11), 614
Equipment
- State-of-the-art facilities for cell culture including 5 class A cell cabinets: one dedicated for LPS and RNAse free cell culture and one dedicated for infected tissues
- Fluorescence Activated Cell Sorting (FACS)
- Confocal microscope to perform live cell 4D imaging
- Thermocycler
- Real-time PCR
- Automated Western Blot
- Gel Permeation Chromatography
- High-Performance Liquid Chromatography
- Ultra Performance Liquid Chromatography equipped with fluorescence, UV/Vis and Infrared and light scattering detectors
- Dynamic light scattering unit
- Nanoparticle tracking analysis
- UV and Fluorescence spectroscopy
- Automated liquid handling units
- Nanoparticle production units
Collaborations
- Xavier Salvatella
IRB Barcelona - Francesca Peiro
Physics-University of Barcelona - Kostas Kostarellos
Life Science- University of Manchester/ICN2 - Giorgio Volpe
Chemistry-UCL - Simona Parrinello
Cancer Institute -UCL - Finn Werner
Structural Biology -UCL - Nick Lane
Evolutionary Biology -UCL - Darren Hargraves
Pediatric Neuro-Oncology -UCL - Timothy McHugh
Clinical Microbiology =UCL - Sebastian Brander
Neurology -UCL - Joan Abbott
Physiology -King’s College London - Molly Stevens
Bioengineering -Imperial College London - Stefano Angioletti-Uberti
Materials Science -Imperial College London - Ricardo Sapienza
Physics -Imperial College London - Daan Frenkel
Chemisty-University of Cambridge - Charlotte Williams
Chemistry -University of Oxford - Francesco Gervasio
Pharmacology -University of Geneve/UCL, UK - Francesco Stellacci
Bionegineering -EPFL Switzerland - Tambet Tessalu
Cancer Biology -University of Tartu (Estonia)/ Sanford Burnham Prebys Medical Discovery Institute - Darrel Irvine
Bioengineering -MIT - Xiaohe Tian
Life Sciences University of Anhui - Yupeng Tian
Chemistry University of Anhui - Lei Luo
Pharmacy -Southwest University, China - Kai Luo
HuaXi hospital Sichuan University - Darren Hargrave
Great Ormond Street Hospital, UCLH London - Sebastian Brander
Queen Square National Centre for Neurology, UCLH London
News
A mechanism to cross the blood-brain bareer has been discovered
Giuseppe Battaglia, leader of the IBEC “Molecular Bionics” group and ICREA Research Professor appears in various media for his recent study describing a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain.
IBEC calls society to action to accelerate research against COVID19
The Institute for Bioengineering of Catalonia (IBEC) launches the Faster Future “A por la COVID19” campaign, with the aim of raising the 100.000€ needed to accelerate three research projects in collaboration with hospitals and patients associations.
Researchers discover a mechanism to cross the protective barrier of the brain
An international study led by IBEC researcher Giuseppe Battaglia identifies a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain. This study describes the role of protein LRP1, bringing light to safe and efficient entrance of drugs to the brain.
Imaginenano Online 2020
Imaginenano2020 Online Imaginenano2020 organisers have been closely monitoring global developments of the COVID-19 virus since the start of the year. The health and safety of our speakers, exhibitors, participants and…
Range selectivity, a new concept that could lead to more efficient nanoparticle drug delivery
In a new study published in the scientific journal Nature Communications, researchers describe a new concept called “range selectivity”, explaining why biomimetic nanoparticles only bind to receptors when their density is within a precise range.
This finding could pave the way for the development of highly targeted therapies against a number of diseases.
Bioengineering against the most resistant and deadly bacterial infections
An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses.
This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.
A “faster and safer” therapy against tuberculosis
A team of international scientists led by the Institute for Bioengineering of Catalonia (IBEC) has developed a “faster, more effective and safer” therapy to eliminate infections of intracellular bacteria that cause diseases such as tuberculosis. Scientists participating in the study include Group Leader Giuseppe Battaglia and the researcher Loris Rizzello of IBEC.
IBEC researchers develop a model to design precision nanomedicine
Researchers at Institute for Bioengineering of Catalonia (IBEC) have proposed a model that gives important insights into how nanoparticles interact with cells, virus, bacteria or proteins, among others.
The findings provide a very powerful tool to design personalized nanomedicines, since allow the scientists to create nanoparticles tailor-made for each patient.
A mechanism to cross the blood-brain bareer has been discovered
Giuseppe Battaglia, leader of the IBEC “Molecular Bionics” group and ICREA Research Professor appears in various media for his recent study describing a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain.
IBEC calls society to action to accelerate research against COVID19
The Institute for Bioengineering of Catalonia (IBEC) launches the Faster Future “A por la COVID19” campaign, with the aim of raising the 100.000€ needed to accelerate three research projects in collaboration with hospitals and patients associations.
Researchers discover a mechanism to cross the protective barrier of the brain
An international study led by IBEC researcher Giuseppe Battaglia identifies a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain. This study describes the role of protein LRP1, bringing light to safe and efficient entrance of drugs to the brain.
Imaginenano Online 2020
Imaginenano2020 Online Imaginenano2020 organisers have been closely monitoring global developments of the COVID-19 virus since the start of the year. The health and safety of our speakers, exhibitors, participants and…
Range selectivity, a new concept that could lead to more efficient nanoparticle drug delivery
In a new study published in the scientific journal Nature Communications, researchers describe a new concept called “range selectivity”, explaining why biomimetic nanoparticles only bind to receptors when their density is within a precise range.
This finding could pave the way for the development of highly targeted therapies against a number of diseases.
Bioengineering against the most resistant and deadly bacterial infections
An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses.
This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.
A “faster and safer” therapy against tuberculosis
A team of international scientists led by the Institute for Bioengineering of Catalonia (IBEC) has developed a “faster, more effective and safer” therapy to eliminate infections of intracellular bacteria that cause diseases such as tuberculosis. Scientists participating in the study include Group Leader Giuseppe Battaglia and the researcher Loris Rizzello of IBEC.
IBEC researchers develop a model to design precision nanomedicine
Researchers at Institute for Bioengineering of Catalonia (IBEC) have proposed a model that gives important insights into how nanoparticles interact with cells, virus, bacteria or proteins, among others.
The findings provide a very powerful tool to design personalized nanomedicines, since allow the scientists to create nanoparticles tailor-made for each patient.